Nuveen’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Nuveen’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-80,353	Closed	-$278K	–	3607
2021 Q1	$278K	Sell	80,353 -18,503	-19%	-$75.1K	﹤0.01%	3187
2020 Q4	$332K	Buy	98,856 +154	+0.2%	+$551	﹤0.01%	3118
2020 Q3	$347K	Buy	98,702 +66,347	+205%	+$267K	﹤0.01%	3046
2020 Q2	$149K	Sell	32,355 -10,146	-24%	-$44.9K	﹤0.01%	3135
2020 Q1	$141K	Buy	42,501 +5,488	+15%	+$25.1K	﹤0.01%	3038
2019 Q4	$226K	Sell	37,013 -1,881	-5%	-$7.75K	﹤0.01%	3064
2019 Q3	$162K	Buy	38,894 +3,719	+11%	+$29.7K	﹤0.01%	3138
2019 Q2	$462K	Buy	+35,175	New	+$431K	﹤0.01%	3032

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nuveen's PHAS Position: Q2 2021 in Review

Nuveen sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 80,353 shares — an estimated $278K sold.

Nuveen first reported a position in PHAS in Q2 2019 and held it in 8 quarters. The position peaked at $462K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

Nuveen reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Nuveen sold 80,353 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $278K.
Nuveen first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
Nuveen's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $462K in Q2 2019.
55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.